Cannabidiol for COVID-19 patients with mild to moderate symptoms (CANDIDATE study): a randomized, double-blind, placebo-controlled clinical trial (2022)
- Authors:
- Crippa, José Alexandre de Souza
- Pacheco, Júlia Cozar
- Zuardi, Antônio Waldo
- Guimarães, Francisco Silveira
- Campos, Alline Cristina de
- Osório, Flávia de Lima
- Loureiro, Sonia Regina
- Santos, Rafael Guimarães dos
- souza, José Diogo dos Santos
- Ushirohira, Juliana Mayumi
- Ferreira, Rafael Rinaldi
- Costa, Karla Cristinne Mancini
- Scomparin, Davi Silveira
- Scarante, Franciele Franco
- Santos, Isabela Pires dos
- Mechoulam, Raphael
- Kapczinski, Flávio
- Fonseca, Benedito Antonio Lopes da
- Esposito, Danillo Lucas Alves
- Passos, Afonso Dinis Costa
- Dal-Fabbro, Amaury Lelis
- Bellissimo-Rodrigues, Fernando
- Arruda, Eurico
- Scarpelini, Sandro
- Andraus, Maristela Haddad
- Nather Junior, Júlio Cesar
- Wada, Danilo Tadao
- Santos, Marcel Koenigkam
- Santos, Antonio Carlos dos
- Busatto Filho, Geraldo
- Hallak, Jaime Eduardo Cecilio
- Crippa, José Alexandre de Souza
- USP affiliated authors: CRIPPA, JOSÉ ALEXANDRE DE SOUZA - FMRP ; ZUARDI, ANTONIO WALDO - FMRP ; GUIMARÃES, FRANCISCO SILVEIRA - FMRP ; CAMPOS, ALLINE CRISTINA DE - FMRP ; OSORIO, FLAVIA DE LIMA - FMRP ; LOUREIRO, SONIA REGINA - FMRP ; SANTOS, RAFAEL GUIMARÃES DOS - FMRP ; FONSECA, BENEDITO ANTONIO LOPES DA - FMRP ; PASSOS, AFONSO DINIS COSTA - FMRP ; DAL FABBRO, AMAURY LELIS - FMRP ; RODRIGUES, FERNANDO BELLISSIMO - FMRP ; ARRUDA NETO, EURICO DE - FMRP ; SCARPELINI, SANDRO - FMRP ; SANTOS, MARCEL KOENIGKAM - FMRP ; SANTOS, ANTONIO CARLOS DOS - FMRP ; BUSATTO FILHO, GERALDO - FM ; HALLAK, JAIME EDUARDO CECILIO - FMRP ; PACHECO, JÚLIA COZAR - FMRP ; SOUZA, JOSÉ DIOGO DOS SANTOS - FMRP ; FERREIRA, RAFAEL RINALDI - FMRP ; COSTA, KARLA CRISTINNE MANCINI - FMRP ; SCOMPARIN, DAVI SILVEIRA - FMRP ; SCARANTE, FRANCIELE FRANCO - FMRP ; SANTOS, ISABELA PIRES DOS - FMRP ; ESPOSITO, DANILLO LUCAS ALVES - FMRP
- Unidades: FMRP; FM
- DOI: 10.1089/can.2021.0093
- Subjects: COVID-19; CANABINOIDES; ENSAIO CLÍNICO; DOENÇAS INFECCIOSAS; MEDICINA INTERNA
- Keywords: SARS-CoV-2; COVID-19; Cannabidiol; Clinical trial; Infectious diseases; Internal medicine
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher place: New Rochelle
- Date published: 2022
- Source:
- Título do periódico: Cannabis And Cannabinoid Research
- ISSN: 2378-8763
- Volume/Número/Paginação/Ano: v. 7, n. 5, p. 658-669, 2022
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: green
-
ABNT
CRIPPA, José Alexandre de Souza et al. Cannabidiol for COVID-19 patients with mild to moderate symptoms (CANDIDATE study): a randomized, double-blind, placebo-controlled clinical trial. Cannabis And Cannabinoid Research, v. 7, n. 5, p. 658-669, 2022Tradução . . Disponível em: https://doi.org/10.1089/can.2021.0093. Acesso em: 14 maio 2024. -
APA
Crippa, J. A. de S., Pacheco, J. C., Zuardi, A. W., Guimarães, F. S., Campos, A. C. de, Osório, F. de L., et al. (2022). Cannabidiol for COVID-19 patients with mild to moderate symptoms (CANDIDATE study): a randomized, double-blind, placebo-controlled clinical trial. Cannabis And Cannabinoid Research, 7( 5), 658-669. doi:10.1089/can.2021.0093 -
NLM
Crippa JA de S, Pacheco JC, Zuardi AW, Guimarães FS, Campos AC de, Osório F de L, Loureiro SR, Santos RG dos, souza JD dos S, Ushirohira JM, Ferreira RR, Costa KCM, Scomparin DS, Scarante FF, Santos IP dos, Mechoulam R, Kapczinski F, Fonseca BAL da, Esposito DLA, Passos ADC, Dal-Fabbro AL, Bellissimo-Rodrigues F, Arruda E, Scarpelini S, Andraus MH, Nather Junior JC, Wada DT, Santos MK, Santos AC dos, Busatto Filho G, Hallak JEC. Cannabidiol for COVID-19 patients with mild to moderate symptoms (CANDIDATE study): a randomized, double-blind, placebo-controlled clinical trial [Internet]. Cannabis And Cannabinoid Research. 2022 ; 7( 5): 658-669.[citado 2024 maio 14 ] Available from: https://doi.org/10.1089/can.2021.0093 -
Vancouver
Crippa JA de S, Pacheco JC, Zuardi AW, Guimarães FS, Campos AC de, Osório F de L, Loureiro SR, Santos RG dos, souza JD dos S, Ushirohira JM, Ferreira RR, Costa KCM, Scomparin DS, Scarante FF, Santos IP dos, Mechoulam R, Kapczinski F, Fonseca BAL da, Esposito DLA, Passos ADC, Dal-Fabbro AL, Bellissimo-Rodrigues F, Arruda E, Scarpelini S, Andraus MH, Nather Junior JC, Wada DT, Santos MK, Santos AC dos, Busatto Filho G, Hallak JEC. Cannabidiol for COVID-19 patients with mild to moderate symptoms (CANDIDATE study): a randomized, double-blind, placebo-controlled clinical trial [Internet]. Cannabis And Cannabinoid Research. 2022 ; 7( 5): 658-669.[citado 2024 maio 14 ] Available from: https://doi.org/10.1089/can.2021.0093 - Efficacy and safety of cannabidiol plus standard care vs standard care alone for the treatment of emotional exhaustion and Burnout among frontline health care workers during the COVID-19 pandemic: a randomized clinical trial
- Maintained anxiolytic effects of cannabidiol after treatment discontinuation in healthcare workers during the COVID-19 pandemic
- Cannabidiol as a treatment for mental health outcomes among health care workers during the coronavirus disease pandemic. [Carta]
- Adverse effects of oral cannabidiol: an updated systematic review of randomized controlled trials (2020–2022)
- Case report: cannabidiol-induced skin rash: a case series and key recommendations
- Modulation of the endocannabinoid and oxytocinergic systems as a potential treatment approach for social anxiety disorder
- Cannabinoids for the treatment of mental disorders [Carta]
- The anxiolytic effects of cannabidiol (CBD)
- Spontaneous activity of CB2 receptors attenuates stress-induced behavioral and neuroplastic deficits in male mice
- Cannabidiol for the treatment of drug use disorders
Informações sobre o DOI: 10.1089/can.2021.0093 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
